Erlonat 150 mg (Erlotinib)

Description

Erlonat 150 mg is a generic variant of Erlotinib which is a drug used primarily for the treatment of lung cancer that is non-small cell (NSCLC) as well as pancreatic cancer. Below is a comprehensive description of Erlonat 150 mg:

If you need buy Fempro 2.5 mg (Letrozole) you can purchase now our generic corners medicine.

Mechanism of Action

• Erlotinib is an inhibitor of tyrosine-kinase kinase that targets specifically epidermal growth factors receptor (EGFR). By blocking EGFR, Erlonat prevents cancer cell proliferation and triggers cell death.

Indications

• Non-Small Cell Lung cancer (NSCLC): It is indicated as the first-line treatment for patients suffering from metastatic NSCLC with EGFR deletions of exon 19 or exon 21 (L858R) substitution mutations.
• Pancreatic Cancer Erlotinib is administered in conjunction with gemcitabine to aid in treatment of patients suffering from locally advanced, unresectable or metastatic pancreatic cancer.

Erlonat 150 mg Dosage and Administration

• The recommended dosage of Erlonat 150 mg for NSCLC is 150 mg taken orally every day.
• To treat pancreatic cancer dosage is 100 mg administered orally, every day, and in conjunction with gemcitabine.

Administration Instructions

• Consume Erlonat 150 mg at least an hour prior to or two hours after eating.
• Don’t crush or break them. Instead, take them whole with water.
• If you miss a dose then take it as quickly as you remember, unless it is near the date of your next dose. Do not increase the dosage in order to cover the missed dose.

Related Pills:  Erlonat 100 mg (Erlotinib) | Erlocip 150 mg (Erlotinib) | Erlocip 100 mg (Erlotinib)

What is a Erlonat 150 mg Side Effects?

Common side effects are:

• Rash
• Diarrhea
• Appetite loss
• Fatigue
• Nausea and vomiting

Some of the most serious side effects are:

• Interstitial lung disease
• Liver toxicity
• Gastrointestinal perforation
• Skin reactions that are severe

Contraindications

• Hypersensitivity to Erlotinib or any other component of the drug.

Warnings and Precautions

• Hepatotoxicity Monitoring of the liver function regularly is highly recommended.
• Pulmonary Toxicity Do not discontinue treatment if the appearance of new or unprovoked pulmonary symptoms is observed.
• Gastrointestinal Perforation Be cautious in patients who have the history of peptic-ulcer disease or diverticulitis.
• Ocular Diseases: The cornea has been reported to have ulceration or severe perforation has been reported.

Drug Interactions

• CYP3A4 inhibitors/inducers Combining CYP3A4 inducers or inhibitors may modify Erlonat levels in blood.
• Warfarin: Increases the risk of bleeding. Monitoring of prothrombin times regularly or INR is recommended.
• Proton pump inhibitors reduce the absorption of Erlonat 150 mg.

Erlonat 150 mg Use in Specific Populations

• Pregnancy: Category D. There is evidence of human fetal risk. The benefits could justify the use of this method despite the potential risks.
• Lactation: Breastfeeding is not advised when you are taking Erlonat 150 mg.
• Pediatrics: Safety and effectiveness are not yet established.
• Geriatrics Not much difference in safety or efficacy as compared to younger patients however, sensitivity increases for older patients cannot be excluded.

Storage

• Keep the temperature at room temperatures between 15 and 30degC (59-86degF).
• Place the medication in the original container. Keep it tightly sealed and out of the reach of children.